Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Treasury Shares (2019 - 2025)

Cyclerion Therapeutics has reported Treasury Shares over the past 7 years, most recently at $119102.0 for Q3 2025.

  • Quarterly results put Treasury Shares at $119102.0 for Q3 2025, down 33.54% from a year ago — trailing twelve months through Sep 2025 was $119102.0 (down 33.54% YoY), and the annual figure for FY2024 was $164174.0, down 3.96%.
  • Treasury Shares for Q3 2025 was $119102.0 at Cyclerion Therapeutics, down from $134126.0 in the prior quarter.
  • Over the last five years, Treasury Shares for CYCN hit a ceiling of $809417.0 in Q1 2023 and a floor of $34362.0 in Q2 2023.
  • Median Treasury Shares over the past 5 years was $141243.5 (2021), compared with a mean of $167280.7.
  • Biggest five-year swings in Treasury Shares: plummeted 74.6% in 2022 and later skyrocketed 465.22% in 2024.
  • Cyclerion Therapeutics' Treasury Shares stood at $92804.0 in 2021, then plummeted by 59.39% to $37686.0 in 2022, then soared by 353.58% to $170937.0 in 2023, then dropped by 3.96% to $164174.0 in 2024, then fell by 27.45% to $119102.0 in 2025.
  • The last three reported values for Treasury Shares were $119102.0 (Q3 2025), $134126.0 (Q2 2025), and $149150.0 (Q1 2025) per Business Quant data.